• 文献检索
  • 文档翻译
  • 深度研究
  • 学术资讯
  • Suppr Zotero 插件Zotero 插件
  • 邀请有礼
  • 套餐&价格
  • 历史记录
应用&插件
Suppr Zotero 插件Zotero 插件浏览器插件Mac 客户端Windows 客户端微信小程序
定价
高级版会员购买积分包购买API积分包
服务
文献检索文档翻译深度研究API 文档MCP 服务
关于我们
关于 Suppr公司介绍联系我们用户协议隐私条款
关注我们

Suppr 超能文献

核心技术专利：CN118964589B侵权必究
粤ICP备2023148730 号-1Suppr @ 2026

文献检索

告别复杂PubMed语法，用中文像聊天一样搜索，搜遍4000万医学文献。AI智能推荐，让科研检索更轻松。

立即免费搜索

文件翻译

保留排版，准确专业，支持PDF/Word/PPT等文件格式，支持 12+语言互译。

免费翻译文档

深度研究

AI帮你快速写综述，25分钟生成高质量综述，智能提取关键信息，辅助科研写作。

立即免费体验

Hypertension, proteinuria, and antagonism of vascular endothelial growth factor signaling: clinical toxicity, therapeutic target, or novel biomarker?

作者信息

van Heeckeren Willem J, Ortiz Jose, Cooney Matthew M, Remick Scot C

出版信息

J Clin Oncol. 2007 Jul 20;25(21):2993-5. doi: 10.1200/JCO.2007.11.5113.

DOI:10.1200/JCO.2007.11.5113
PMID:17634476
Abstract
摘要

相似文献

1
Hypertension, proteinuria, and antagonism of vascular endothelial growth factor signaling: clinical toxicity, therapeutic target, or novel biomarker?高血压、蛋白尿与血管内皮生长因子信号传导拮抗作用：临床毒性、治疗靶点还是新型生物标志物？
J Clin Oncol. 2007 Jul 20;25(21):2993-5. doi: 10.1200/JCO.2007.11.5113.
2
Hypertension and proteinuria: a class-effect of antiangiogenic therapies.高血压与蛋白尿：抗血管生成疗法的类效应
Anticancer Drugs. 2009 Jan;20(1):81-2. doi: 10.1097/CAD.0b013e3283161012.
3
Current concerns and challenges regarding tailored anti-angiogenic therapy in cancer.当前癌症个体化抗血管生成治疗的关注点与挑战。
Expert Rev Anticancer Ther. 2009 Oct;9(10):1413-6. doi: 10.1586/era.09.116.
4
Novel angiogenesis inhibitors: addressing the issue of redundancy in the angiogenic signaling pathway.新型血管生成抑制剂：解决血管生成信号通路中的冗余问题。
Cancer Treat Rev. 2011 Aug;37(5):344-52. doi: 10.1016/j.ctrv.2011.02.002. Epub 2011 Mar 23.
5
Is the toxicity of anti-angiogenic drugs predictive of outcome? A review of hypertension and proteinuria as biomarkers of response to anti-angiogenic therapy.抗血管生成药物的毒性是否可预测疗效？以高血压和蛋白尿作为抗血管生成治疗反应的生物标志物的综述。
Expert Opin Drug Metab Toxicol. 2012 Mar;8(3):283-93. doi: 10.1517/17425255.2012.656845. Epub 2012 Jan 30.
6
Response to anti-angiogenesis: an ever changing feature.抗血管生成反应：一个不断变化的特征。
Breast. 2011 Oct;20 Suppl 3:S61-2. doi: 10.1016/S0960-9776(11)70296-X.
7
Phase I dose escalation study of telatinib, a tyrosine kinase inhibitor of vascular endothelial growth factor receptor 2 and 3, platelet-derived growth factor receptor beta, and c-Kit, in patients with advanced or metastatic solid tumors.在晚期或转移性实体瘤患者中开展的一项关于替拉替尼（一种血管内皮生长因子受体2和3、血小板衍生生长因子受体β以及c-Kit的酪氨酸激酶抑制剂）的I期剂量递增研究。
J Clin Oncol. 2009 Sep 1;27(25):4169-76. doi: 10.1200/JCO.2008.18.8193. Epub 2009 Jul 27.
8
Antiangiogenic therapy for cancer: an update.癌症的抗血管生成疗法：最新进展
Cancer J. 2007 Nov-Dec;13(6):345-8. doi: 10.1097/PPO.0b013e31815a7b69.
9
Retinal anti-angiogenesis by a new route.通过新途径实现视网膜抗血管生成。
Nat Biotechnol. 2008 May;26(5):528-9. doi: 10.1038/nbt0508-528.
10
Proteinuria and VEGF-targeted therapies: 
an underestimated toxicity?蛋白尿与VEGF靶向治疗：一种被低估的毒性？
J Nephrol. 2013 Sep-Oct;26(5):807-10. doi: 10.5301/jn.5000307. Epub 2013 Aug 7.

引用本文的文献

1
Exploitation of enhanced prime editing for blocking aberrant angiogenesis.利用增强型碱基编辑技术阻断异常血管生成。
J Adv Res. 2025 Jun;72:121-133. doi: 10.1016/j.jare.2024.07.006. Epub 2024 Jul 10.
2
Anti-Angiogenic Therapy: Albumin-Binding Proteins Could Mediate Mechanisms Underlying the Accumulation of Small Molecule Receptor Tyrosine Kinase Inhibitors in Normal Tissues with Potential Harmful Effects on Health.抗血管生成疗法：白蛋白结合蛋白可能介导小分子受体酪氨酸激酶抑制剂在正常组织中蓄积的潜在健康有害机制。
Diseases. 2021 Apr 10;9(2):28. doi: 10.3390/diseases9020028.
3
Apatinib as first-line treatment in patients with advanced hepatocellular carcinoma: a phase II clinical trial.
阿帕替尼作为晚期肝细胞癌患者的一线治疗：一项II期临床试验。
Ann Transl Med. 2020 Sep;8(17):1047. doi: 10.21037/atm-20-2990.
4
Expression of fibroblast growth factor receptor 4 and clinical response to lenvatinib in patients with anaplastic thyroid carcinoma: a pilot study.成纤维细胞生长因子受体 4 的表达与仑伐替尼治疗甲状腺未分化癌的临床疗效：一项初步研究。
Eur J Clin Pharmacol. 2020 May;76(5):703-709. doi: 10.1007/s00228-020-02842-y. Epub 2020 Feb 7.
5
Hypertension Caused by Lenvatinib and Everolimus in the Treatment of Metastatic Renal Cell Carcinoma.乐伐替尼和依维莫司治疗转移性肾细胞癌引起的高血压
Int J Mol Sci. 2017 Aug 10;18(8):1736. doi: 10.3390/ijms18081736.
6
Analysis of adverse events of sunitinib in patients treated for advanced renal cell carcinoma.舒尼替尼治疗晚期肾细胞癌患者的不良事件分析。
Arch Med Sci. 2016 Apr 1;12(2):360-4. doi: 10.5114/aoms.2016.59262. Epub 2016 Apr 12.
7
Cardiovascular Toxicity of Molecular Targeted Therapy in Cancer Patients: A Double-Edged Sword.癌症患者分子靶向治疗的心血管毒性：一把双刃剑
Acta Cardiol Sin. 2013 Jul;29(4):295-303.
8
Retrospective analysis of bevacizumab-induced hypertension and clinical outcome in patients with colorectal cancer and lung cancer.贝伐单抗诱发结直肠癌和肺癌患者高血压及临床结局的回顾性分析
Cancer Med. 2016 Jul;5(7):1381-7. doi: 10.1002/cam4.701. Epub 2016 Apr 25.
9
Targeting prion-like protein doppel selectively suppresses tumor angiogenesis.靶向朊病毒样蛋白多配体可选择性抑制肿瘤血管生成。
J Clin Invest. 2016 Apr 1;126(4):1251-66. doi: 10.1172/JCI83427. Epub 2016 Mar 7.
10
Sunitinib-associated hypertension and neutropenia as efficacy biomarkers in metastatic renal cell carcinoma patients.舒尼替尼相关的高血压和中性粒细胞减少作为转移性肾细胞癌患者疗效生物标志物
Br J Cancer. 2015 Dec 1;113(11):1571-80. doi: 10.1038/bjc.2015.368. Epub 2015 Oct 22.